Last reviewed · How we verify

allovectin-7/dacarbazine

Vical · Phase 3 active Small molecule

allovectin-7/dacarbazine is a DNA vaccine, chemotherapy Small molecule drug developed by Vical. It is currently in Phase 3 development for Metastatic melanoma.

Allovectin-7 is a DNA vaccine that targets telomerase, while dacarbazine is a chemotherapy drug that interferes with DNA replication.

Allovectin-7 is a DNA vaccine that targets telomerase, while dacarbazine is a chemotherapy drug that interferes with DNA replication. Used for Metastatic melanoma.

At a glance

Generic nameallovectin-7/dacarbazine
SponsorVical
Drug classDNA vaccine, chemotherapy
TargetTelomerase
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Allovectin-7 works by stimulating an immune response against telomerase, a protein that is overexpressed in many cancer cells. Dacarbazine, on the other hand, is a alkylating agent that adds an alkyl group to DNA, causing cross-linking and interfering with DNA replication, ultimately leading to cell death.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about allovectin-7/dacarbazine

What is allovectin-7/dacarbazine?

allovectin-7/dacarbazine is a DNA vaccine, chemotherapy drug developed by Vical, indicated for Metastatic melanoma.

How does allovectin-7/dacarbazine work?

Allovectin-7 is a DNA vaccine that targets telomerase, while dacarbazine is a chemotherapy drug that interferes with DNA replication.

What is allovectin-7/dacarbazine used for?

allovectin-7/dacarbazine is indicated for Metastatic melanoma.

Who makes allovectin-7/dacarbazine?

allovectin-7/dacarbazine is developed by Vical (see full Vical pipeline at /company/vical).

What drug class is allovectin-7/dacarbazine in?

allovectin-7/dacarbazine belongs to the DNA vaccine, chemotherapy class. See all DNA vaccine, chemotherapy drugs at /class/dna-vaccine-chemotherapy.

What development phase is allovectin-7/dacarbazine in?

allovectin-7/dacarbazine is in Phase 3.

What are the side effects of allovectin-7/dacarbazine?

Common side effects of allovectin-7/dacarbazine include Fatigue, Nausea, Vomiting, Diarrhea, Anemia.

What does allovectin-7/dacarbazine target?

allovectin-7/dacarbazine targets Telomerase and is a DNA vaccine, chemotherapy.

Related